InTrack Investment Management Inc Purchases 660 Shares of Eli Lilly and Company $LLY

InTrack Investment Management Inc increased its holdings in Eli Lilly and Company (NYSE:LLY) by 24.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,380 shares of the company’s stock after purchasing an additional 660 shares during the quarter. Eli Lilly and Company makes up approximately 1.5% of InTrack Investment Management Inc’s holdings, making the stock its 20th largest holding. InTrack Investment Management Inc’s holdings in Eli Lilly and Company were worth $2,579,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of LLY. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company in the second quarter valued at $29,000. Steph & Co. increased its position in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc raised its holdings in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LLY shares. Wolfe Research lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. CICC Research lifted their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Daiwa America upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 16th. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Five analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $1,161.27.

Eli Lilly and Company Trading Down 3.6%

Eli Lilly and Company stock opened at $1,041.78 on Tuesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a market capitalization of $984.88 billion, a price-to-earnings ratio of 50.97, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The business’s fifty day simple moving average is $1,017.48 and its two-hundred day simple moving average is $853.10. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.